These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 33537544)

  • 1. ADAMTS13 and von Willebrand factor assessment in steady state and acute vaso-occlusive crisis of sickle cell disease.
    Demagny J; Driss A; Stepanian A; Anguel N; Affo L; Roux D; Habibi A; Benghezal S; Capdenat S; Coppo P; Driss F; Veyradier A
    Res Pract Thromb Haemost; 2021 Jan; 5(1):197-203. PubMed ID: 33537544
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dynamics of von Willebrand factor reactivity in sickle cell disease during vaso-occlusive crisis and steady state.
    Sins JWR; Schimmel M; Luken BM; Nur E; Zeerleder SS; van Tuijn CFJ; Brandjes DPM; Kopatz WF; Urbanus RT; Meijers JCM; Biemond BJ; Fijnvandraat K
    J Thromb Haemost; 2017 Jul; 15(7):1392-1402. PubMed ID: 28457019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ADAMTS13 activity in sickle cell disease.
    Schnog JJ; Kremer Hovinga JA; Krieg S; Akin S; Lämmle B; Brandjes DP; Mac Gillavry MR; Muskiet FD; Duits AJ;
    Am J Hematol; 2006 Jul; 81(7):492-8. PubMed ID: 16755558
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment with recombinant ADAMTS13, alleviates hypoxia/reoxygenation-induced pathologies in a mouse model of human sickle cell disease.
    Rossato P; Glantschnig H; Canneva F; Schuster M; Coulibaly S; Schrenk G; Voelkel D; Dockal M; Plaimauer B; Rottensteiner H; Gritsch H; Federti E; Matte A; De Franceschi L; Scheiflinger F; Hoellriegl W
    J Thromb Haemost; 2023 Feb; 21(2):269-275. PubMed ID: 36700507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contribution of ADAMTS13-independent VWF regulation in sickle cell disease.
    Hunt RC; Katneni U; Yalamanoglu A; Indig FE; Ibla JC; Kimchi-Sarfaty C
    J Thromb Haemost; 2022 Sep; 20(9):2098-2108. PubMed ID: 35753044
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determination of the level of von willebrand factor and ADAMTS13 in sickle cell anaemia patients in steady state.
    Kingsley A; Ofonime E; Enobong U; Iquo I
    Niger J Clin Pract; 2022 Sep; 25(9):1393-1397. PubMed ID: 36149195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determination of von Willebrand factor level in patient with sickle cell diseasein vaso-occlusive crisis.
    Akaba K; Nwogoh B; Oshatuyi O
    Res Pract Thromb Haemost; 2020 Jul; 4(5):902-905. PubMed ID: 32685901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ADAMTS-13-VWF axis in sickle cell disease patients.
    Ladeira VS; Barbosa AR; Oliveira MM; Ferreira LGR; de Oliveira Júnior WV; de Oliveira Renó C; Reis EA; Chaves DG; Dusse LMS; Dos Santos HL; de Barros Pinheiro M; Rios DRA
    Ann Hematol; 2021 Feb; 100(2):375-382. PubMed ID: 33404693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endothelial VWF is critical for the pathogenesis of vaso-occlusive episode in a mouse model of sickle cell disease.
    Shi H; Shao B; Gao L; Venkatesan T; McDaniel JM; Zhou M; McGee S; Yu P; Ahamed J; Journeycake J; George JN; Xia L
    Proc Natl Acad Sci U S A; 2022 Aug; 119(34):e2207592119. PubMed ID: 35969769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The ADAMTS13-von Willebrand factor axis in COVID-19 patients.
    Mancini I; Baronciani L; Artoni A; Colpani P; Biganzoli M; Cozzi G; Novembrino C; Boscolo Anzoletti M; De Zan V; Pagliari MT; Gualtierotti R; Aliberti S; Panigada M; Grasselli G; Blasi F; Peyvandi F
    J Thromb Haemost; 2021 Feb; 19(2):513-521. PubMed ID: 33230904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma PTX3 levels in sickle cell disease patients, during vaso occlusion and acute chest syndrome (data from Saudi population).
    Elshazly SA; Heiba NM; Abdelmageed WM
    Hematology; 2014 Jan; 19(1):52-9. PubMed ID: 23735470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ADAMTS13 activity to von Willebrand factor antigen ratio predicts acute kidney injury in patients with COVID-19: Evidence of SARS-CoV-2 induced secondary thrombotic microangiopathy.
    Henry BM; Benoit SW; de Oliveira MHS; Lippi G; Favaloro EJ; Benoit JL
    Int J Lab Hematol; 2021 Jul; 43 Suppl 1(Suppl 1):129-136. PubMed ID: 33270980
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Levels and activities of von Willebrand factor and metalloproteinase with thrombospondin type-1 motif, number 13 in inflammatory bowel diseases.
    Cibor D; Owczarek D; Butenas S; Salapa K; Mach T; Undas A
    World J Gastroenterol; 2017 Jul; 23(26):4796-4805. PubMed ID: 28765701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased von Willebrand factor over decreased ADAMTS13 activity may contribute to the development of liver disturbance and multiorgan failure in patients with alcoholic hepatitis.
    Matsuyama T; Uemura M; Ishikawa M; Matsumoto M; Ishizashi H; Kato S; Morioka C; Fujimoto M; Kojima H; Yoshiji H; Takimura C; Fujimura Y; Fukui H
    Alcohol Clin Exp Res; 2007 Jan; 31(1 Suppl):S27-35. PubMed ID: 17331163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of hydroxyurea therapy on intravascular hemolysis and endothelial dysfunction markers in sickle cell anemia patients.
    Chenou F; Hounkpe BW; Domingos IF; Tonassé WV; Batista THC; Santana RM; Arcanjo GDS; Alagbe AE; Araújo ADS; Lucena-Araújo AR; Bezerra MAC; Costa FF; Sonati MF; De Paula EV; Dos Santos MNN
    Ann Hematol; 2021 Nov; 100(11):2669-2676. PubMed ID: 34453189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence of protective effects of recombinant ADAMTS13 in a humanized model of sickle cell disease.
    Rossato P; Federti E; Matte A; Glantschnig H; Canneva F; Schuster M; Coulibaly S; Schrenk G; Voelkel D; Dockal M; Plaimauer B; Andolfo I; Iolascon A; Rottensteiner H; Gritsch H; Scheiflinger F; Hoellriegl W; Franceschi L
    Haematologica; 2022 Nov; 107(11):2650-2660. PubMed ID: 35443560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The rate of hemolysis in sickle cell disease correlates with the quantity of active von Willebrand factor in the plasma.
    Chen J; Hobbs WE; Le J; Lenting PJ; de Groot PG; López JA
    Blood; 2011 Mar; 117(13):3680-3. PubMed ID: 21300978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Magnetic Resonance Imaging Assessment of Kidney Oxygenation and Perfusion During Sickle Cell Vaso-occlusive Crises.
    Deux JF; Audard V; Brugières P; Habibi A; Manea EM; Guillaud-Danis C; Godeau B; Galactéros F; Stehlé T; Lang P; Grimbert P; Audureau E; Rahmouni A; Bartolucci P
    Am J Kidney Dis; 2017 Jan; 69(1):51-59. PubMed ID: 27663041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. VWF-ADAMTS13 axis dysfunction in children with sickle cell disease treated with hydroxycarbamide vs blood transfusion.
    Fogarty H; Ahmad A; Atiq F; Doherty D; Ward S; Karampini E; Rehill A; Leon G; Byrne C; Geoghegan R; Conroy H; Byrne M; Budde U; Schneppenheim S; Sheehan C; Ngwenya N; Baker RI; Preston RJS; Tuohy E; McMahon C; O'Donnell JS
    Blood Adv; 2023 Nov; 7(22):6974-6989. PubMed ID: 37773926
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patterns of arginine and nitric oxide in patients with sickle cell disease with vaso-occlusive crisis and acute chest syndrome.
    Morris CR; Kuypers FA; Larkin S; Vichinsky EP; Styles LA
    J Pediatr Hematol Oncol; 2000; 22(6):515-20. PubMed ID: 11132219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.